ARK Genomic Revolution ETF (ARKG)
| Assets | $2.19B |
| Expense Ratio | 0.75% |
| PE Ratio | n/a |
| Shares Out | 67.00M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Dec 29, 2021 |
| Payout Ratio | n/a |
| 1-Year Return | -33.74% |
| Volume | 1,055,562 |
| Open | 32.87 |
| Previous Close | 32.70 |
| Day's Range | 32.83 - 33.73 |
| 52-Week Low | 26.38 |
| 52-Week High | 52.47 |
| Beta | 1.45 |
| Holdings | 47 |
| Inception Date | Oct 31, 2014 |
About ARKG
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Top 10 Holdings
50.65% of assets| Name | Symbol | Weight |
|---|---|---|
| Exact Sciences Corporation | EXAS | 11.66% |
| Pacific Biosciences of California, Inc. | PACB | 5.72% |
| Teladoc Health, Inc. | TDOC | 4.88% |
| Ionis Pharmaceuticals, Inc. | IONS | 4.77% |
| CareDx, Inc | CDNA | 4.29% |
| Beam Therapeutics Inc. | BEAM | 4.10% |
| SCHRODINGER INC | SDGR | 3.97% |
| Adaptive Biotechnologies Corporation | ADPT | 3.82% |
| Twist Bioscience Corporation | TWST | 3.75% |
| Ginkgo Bioworks Holdings, Inc. | DNA | 3.69% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 29, 2021 | $0.38239 | Dec 31, 2021 |
| Dec 29, 2020 | $0.42557 | Dec 31, 2020 |
| Dec 27, 2019 | $1.05395 | Dec 31, 2019 |
| Dec 27, 2018 | $0.26999 | Dec 31, 2018 |
| Dec 27, 2017 | $0.19272 | Dec 29, 2017 |
News
Get Benefits From Innovator ACCD in Health Tech ETF ARKG
For all the concerns surrounding tech investments over the last year, with mega-cap tech names like Amazon (AMZN) and Meta (META) being the poster children for the broad market selloff, biotech remain...
Best ETF Areas of Last Week
Wall Street was pretty upbeat last week due to cooling inflation.
EXAS Nears Key Buy Signal in Active Biotech ETF ARKG
There are a lot of reasons to be skeptical of tech investing right now since last year's broad market selloff — just how far is the Fed planning to go with rising rates this year, anyway? Still, there...
Why Now Could Be Time to Buy No Cap Gain ARK Strats
Ready for the new year? It wouldn't be surprising for most ETF investors to be excited to put 2022 in the rear view.
Top-Read Disruptive Technology Stories of 2022
2022 has been a wild year for markets, from Russia's invasion of Ukraine to the Fed's dedicated rate hike campaign. That hasn't stopped the world from innovating, though, with firms in areas from biot...
ARK Continues Contrarian Plays in ETFs TSLA, COIN, VERV
ARK Invest and CEO Cathie Wood have once again bought the dip on firms the company believes have long term potential to be real innovators, adding shares from Tesla (TSLA), Coinbase (COIN), and Verve ...
Gene Editing Stock in ARKG Gets Buy Rating
2022 hasn't been a great year for all kinds of tech stocks, and certainly biotech has taken its fair share of lumps as interest rates have continued to dry up funding. That hasn't stopped the innovati...
Why a Biotech ETF Might Cure Your Portfolio in 2023
While the headlines have focused on a crypto winter, it hasn't exactly been an easy year for biotech. The sector that blossomed amid a global pandemic has struggled with the pandemic easing and rates ...
Why This Biotech Firm is the Top Weight in ARKG
You may have missed it over Thanksgiving week, but there's reason to be excited about at least one biotech firm on the market. Exact Sciences Corp (EXAS) was recently the subject of positive attention...
ARK Completes Move to Florida With Broad Research Team
ARK Invest, which manages $14 billion in ETF assets primarily through active, disruptive technology ETFs, moved headquarters last week to Tampa/St. Petersburg, Florida, from New York. The firm runs so...
Biotech Earnings, Market Leap Boost ARKG Potential
This week's soft CPI print has sent the stock market into a flurry of positivity, hitting multi-year highs on Thursday as investor optimism leaped forward.
As Flu Season Consumers Prefer Telehealth, Watch ARKG
Telehealth options remain very popular with consumers for routine appointments, according to a recent survey, preferred to in-person options for routine care.
ARKG Holding PacBio's 1-Month Returns Top 48%
ARK Genomic Revolution ETF (ARKG) holding Pacific Biosciences (PACB) opened lower on Monday but is still posting one-month returns topping 48%. Shares of Pacific Biosciences traded up around 16% last...
ARKG Holding Senti Biosciences Increases 22% Thursday as Markets Rally
U.S. equities across all sectors are rebounding Thursday following the release of a hotter-than-expected inflation report. After recent volatility, shares of Senti Biosciences have increased nearly 2...
ARKK Takes in Nearly Half Billion in September Flows
The ARK Innovation ETF (ARKK) accreted nearly half a billion dollars from investors in September. ARK Invest's flagship fund saw $441 million in net inflows in September, bringing the year-to-date net...
Positive Sentiment in Biotech Intensifies, Add ARKG
Last week saw significant volatility. However, positive sentiment intensified throughout the biotech space, propelled by favorable legislation and encouraging trial data.
ARKG Offers Exposure to Advancements in Synthetic Biology
New advances in synthetic biology uncovers lucrative investment opportunities for advisors.
Shares of Signify Health Propelled by Buyout Prospects
Shares of Signify Health (SGFY) have continued to trade up on rumors of CVS Health Corp's (CVS) interest in acquiring the company. Signify Health is exploring strategic alternatives, including a sale,...
Opportunities Emerge From Rapid Cost Declines in Gene Editing and Synthesis
The rapid cost declines associated with gene editing and gene synthesis are turbo-charging scientific creativity, enabling the testing of hypotheses that, until now, have been cost-prohibitive, ARK In...
ARKG Holding Butterfly Network Increases 127% in Past Month
Biotech stocks got crushed in the first half of the year as a risk-off sentiment emerged and the growthiest segments of the market were punished, but have rebounded in recent months, with some compani...
ARKG Top Holding Signify Reported to Be Acquisition Target by CVS
CVS Health Corp (CVS) is seeking to buy Signify Health Inc. (SGFY) as it looks to expand in-home health services, the Wall Street Journal reported on Sunday, citing sources. Signify Health is explorin...
Investors Flocked to ARKK and ARKG in July as Growth Rebounded
Investors reinstated their positions in the growthiest segments of the market in July. After U.S. equities posted their worst first-half performance since 1970 as inflation concerns, Fed rate hikes, a...